1 – 10 of 20
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Validation, Deployment, and Real-World Implementation of a Modular Toolbox for Alzheimer’s Disease Detection and Dementia Risk Reduction : The AD-RIDDLE Project
2024) In Journal of Prevention of Alzheimer's Disease(
- Contribution to journal › Article
- 2023
-
Mark
A longitudinal resource for population neuroscience of school-age children and adolescents in China
(
- Contribution to journal › Article
-
Mark
Screening over Speech in Unselected Populations for Clinical Trials in AD (PROSPECT-AD) : Study Design and Protocol
(
- Contribution to journal › Article
-
Mark
Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab
(
- Contribution to journal › Article
- 2022
-
Mark
Brain charts for the human lifespan
(
- Contribution to journal › Article
-
Mark
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease
(
- Contribution to journal › Article
- 2021
-
Mark
Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework
(
- Contribution to journal › Scientific review
-
Mark
2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
(
- Contribution to journal › Scientific review
-
Mark
SCRT1 is a novel beta cell transcription factor with insulin regulatory properties
(
- Contribution to journal › Article
-
Mark
The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers
(
- Contribution to journal › Scientific review